Auvelity (Dextromethorphan-Bupropion) — Key Takeaways: NMDA Antagonism, Sigma-1 Agonism, and Separating From Placebo at Week One

📇 The Index Card — Key Takeaways

Auvelity (Dextromethorphan-Bupropion)

The case — Sarah, 34, a marketing manager. Third major depressive episode in five years, PHQ-9 around 19, passive “what’s the point” ideation without acute suicidality. Sertraline helped her mood twice, and she stopped it twice — sexual dysfunction and about 15 lb gained were deal-breakers. She has no seizure, eating-disorder, or substance-use history, she cannot wait six weeks in a high-pressure job, and esketamine is not workable: no certified clinic nearby and no way to give up two hours twice a week.

1. Do not re-run a drug that only “kind of worked.” NP Z’s rule from Sarah’s two sertraline trials: return to a past antidepressant only when it genuinely restored functioning and remission — not because it is familiar. “Kind of helped, but I quit it twice for side effects” is a reason to change mechanism, not to repeat the trial.
2. Bupropion is the key that unlocks the pill. On its own, dextromethorphan (the familiar cough suppressant) is rapidly converted by the liver enzyme CYP2D6 to dextrorphan, so little reaches the brain. Bupropion inhibits CYP2D6, slows that conversion, and raises dextromethorphan exposure dramatically — without that blockade, the NMDA and sigma-1 effects below largely disappear.
3. A different paradigm, in a take-home tablet. Dextromethorphan brings NMDA receptor antagonism — blocking a glutamate receptor, the same broad target family as ketamine, tied in the episode to faster effect and neuroplasticity (the brain’s ability to form and strengthen new connections) — plus sigma-1 agonism and some norepinephrine reuptake inhibition. Bupropion adds norepinephrine and dopamine reuptake inhibition, the piece aimed at low drive, fatigue, brain fog, and anhedonia (inability to feel pleasure).
4. The SERT paradox explains the side-effect pitch. Auvelity’s tightest binding is actually to SERT, the serotonin transporter, yet its serotonin reuptake inhibition is roughly 10 to 100 times weaker in potency than classic SSRIs such as sertraline, fluoxetine, or paroxetine, per the episode. NP Z links that weaker serotonergic punch to why sexual dysfunction and emotional blunting can be less prominent than on a full-strength SSRI — a reason it fits Sarah, not a guarantee those effects never occur.
5. Sigma-1 is a chaperone, not a classic receptor. It sits at the junction of the endoplasmic reticulum (the cell’s protein factory) and the mitochondria (its powerhouse) and regulates calcium flow between them — calcium being the neuron’s internal signaling currency, excitotoxic in excess and silencing in deficit. Under cell stress it redeploys and helps counter inflammation and oxidative damage, which is why NP Z flags a possible fit for an inflammatory subtype of depression. For scale: among SSRIs, fluvoxamine is by far the most potent sigma-1 agonist, with only a little of that activity in sertraline and fluoxetine.
6. Speed is the headline — and the trial split is specific. The combination separated from placebo at week one. In the phase 2 trial NP Z cites, remission was 46.5% on dextromethorphan-bupropion versus 16% on bupropion alone — evidence the dextromethorphan component is doing work, not just riding along. Common trade-offs to counsel on instead: dizziness, nausea, headache, tiredness, and dry mouth.
7. Know the boundaries before you reach for it. Per the FDA label, Auvelity is approved for major depressive disorder in adults — it is not proven for treatment-resistant depression, even though NP Z describes reaching for it in practice when esketamine or TMS (transcranial magnetic stimulation) is not viable. It is also not a swap for someone thriving on bupropion XL 450 mg: the full Auvelity dose delivers only 210 mg of bupropion a day, so switching can under-dose that patient. Bupropion’s contraindications still apply — seizure disorder, a current or prior diagnosis of anorexia or bulimia, and abrupt discontinuation of alcohol, benzodiazepines, or other sedatives — and NP Z says he would not combine Auvelity with an SSRI, because the serotonergic overlap would demand careful serotonin-syndrome monitoring and patient education. Counsel, too, that it can contribute to false-positive amphetamine urine screens.

The call for Sarah: Auvelity — titrated to the full combination dose of two tablets a day (dextromethorphan 90 mg / bupropion 210 mg daily, per the FDA label schedule) — chosen for week-one separation, a non-esketamine schedule she can actually keep, and a profile aimed away from the sexual dysfunction and weight gain that ended sertraline twice. NP Z’s closing reminder: there is no free lunch — every new mechanism still carries trade-offs to check first.